Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
20.17
+0.29 (1.48%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Beam Therapeutics Employees
Beam Therapeutics had 483 employees as of December 31, 2024. The number of employees increased by 47 or 10.78% compared to the previous year.
Employees
483
Change (1Y)
47
Growth (1Y)
10.78%
Revenue / Employee
$131,507
Profits / Employee
-$780,004
Market Cap
1.96B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
BEAM News
- 19 days ago - Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress - GlobeNewsWire
- 24 days ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz
- 4 weeks ago - Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration - GlobeNewsWire
- 4 weeks ago - Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy - Seeking Alpha
- 6 weeks ago - Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity - Benzinga
- 6 weeks ago - Beam Therapeutics Announces Pricing of Underwritten Offering - GlobeNewsWire
- 6 weeks ago - Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation - GlobeNewsWire
- 2 months ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts - GlobeNewsWire